Miyoshi, H., Tokutake, N., Imaeda, Y., Akagi, T. and Iwamura, H. (1995) A Model of Antimycin A Binding Based on Structure-Activity Studies of Synthetic Antimycin A Analogue. Biochimica et Biophysica Acta (BBA)—Bioenergetics, 1229, 149-154.
http://dx.doi.org/10.1016/0005-2728(94)00185-8

has been cited by the following article:

• TITLE: Design and Molecular Docking Study of Antimycin A3 Analogues as Inhibitors of Anti-Apoptotic Bcl-2 of Breast Cancer

  AUTHORS: Ade Arsianti,   Fadilah,   Kusmardi, Hiroki Tanimoto, Tsumoru Morimoto, Kiyomi Kakiuchi

  KEYWORDS: Design, Docking, Antimycin A3, Analogue, Bcl-2, Breast Cancer

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.4 No.3, September 23, 2014

  ABSTRACT: In this paper, we report the design and moleculardocking study of analogues of antimycin A3 as inhibitors of anti-apoptotic Bcl-2 of breast cancer. Twenty designed compounds and the original antimycin A3 were docked based on their interaction with breast tumor receptor binding target Bcl-2. The docking resulted in the five top-ranked compounds, namely, compounds 11, 14, 15, 16, and 20, which have a lower G binding energy, better affinity and stronger hydrogen bonding interactions to the active site of Bcl-2 than antimycin A3. Among those five top-ranked compounds, analogue compounds 11 and 14, which have an 18-membered tetralactone core and 18-membered tetraol core, respectively, exhibited the strongest hydrogen bond interaction, formed high stability conformation, and demonstrated the greatest inhibitory activity on the catalytic site of Bcl-2.